IRWD Q3 2023 Earnings — Ironwood Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

IRWDIronwood Pharmaceuticals, Inc.

$629M

Q3 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$114M+4.7% YoY

Gross Profit

$113M99.6% margin

Operating Income

$49M42.7% margin

Net Income

$15M13.5% margin

EPS (Diluted)

$0.08

QoQ Revenue Growth

+5.9%

Cash Flow

Operating Cash Flow

$32M

Free Cash Flow

$32M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$524M

Total Liabilities

$850M

Stockholders' Equity

-$323M

Cash & Equivalents

$110M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$114M	$109M	+4.7%
Gross Profit	$113M	$108M	+4.6%
Operating Income	$49M	$68M	-29.0%
Net Income	$15M	$50M	-69.6%

Revenue Segments

Collaborative arrangement, other agreements

$755,00048%

Collaborative arrangement, collaboration and license agreements

$432,00027%

Royalty

$400,00025%

Geographic Segments

North America

$111M99%

Europe and Other

$714,0001%